Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development

View ORCID ProfileOleksii Nikolaienko, Hans P. Eikesdal, View ORCID ProfileBjørnar Gilje, Steinar Lundgren, Egil S. Blix, Helge Espelid, Jürgen Geisler, Stephanie Geisler, View ORCID ProfileEmiel A.M. Janssen, View ORCID ProfileSynnøve Yndestad, Laura Minsaas, Beryl Leirvaag, Reidun Lillestøl, View ORCID ProfileStian Knappskog, Per E. Lønning
doi: https://doi.org/10.1101/2023.05.14.23289949
Oleksii Nikolaienko
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Oleksii Nikolaienko
Hans P. Eikesdal
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bjørnar Gilje
3Department of Hematology and Oncology, Stavanger University Hospital; Stavanger, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bjørnar Gilje
Steinar Lundgren
4Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital; Trondheim, Norway
5Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology; Trondheim, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Egil S. Blix
6Department of Oncology, University Hospital of North Norway; Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helge Espelid
7Department of Surgery, Haugesund Hospital; Haugesund, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Geisler
8Department of Oncology, Akershus University Hospital; Lørenskog, Norway.
9Institute of Clinical Medicine, University of Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Geisler
8Department of Oncology, Akershus University Hospital; Lørenskog, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emiel A.M. Janssen
10Department of Pathology, Stavanger University Hospital; Stavanger, Norway
11Department of Chemistry, Bioscience and Environmental Engineering; Stavanger University, Stavanger, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emiel A.M. Janssen
Synnøve Yndestad
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Synnøve Yndestad
Laura Minsaas
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beryl Leirvaag
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reidun Lillestøl
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stian Knappskog
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stian Knappskog
Per E. Lønning
1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
2Department of Oncology, Haukeland University Hospital; Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: per.lonning{at}helse-bergen.no
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Data Availability

Haukeland University Hospital and the University of Bergen support the dissemination of research data that has been generated, and increased cooperation between investigators. Trial data is collected, stored, and disseminated according to institutional guidelines and in accordance with national laws and regulations to ensure the quality, integrity, and use of clinical data. Study protocol, including plan for statistical analyses, is available online via previous publications. Signed informed consent forms are stored at each participating hospital and are available for monitoring by regulatory authorities. After publication and upon formal request, raw data, including de-identified individual participant data and a data dictionary defining each field in the data set, will be shared according to institutional procedures. Requests are via a standard pro forma describing the nature of the proposed research and extent of data requirements. Data recipients are required to enter a formal data sharing agreement which describes the conditions for release and requirements for data transfer, storage, archiving, publication, and intellectual property. Requests are reviewed by the EPITAX, DDP and PETREMAC study teams in terms of scientific merit and ethical considerations, including patient consent. Data sharing is permitted if proposed projects have a sound scientific or patient benefit rationale, as agreed by the study team and with approval from the trials' co-investigators as required. Samples from the MoBa study were analyzed blinded to the identity of the participants. Since BRCA1 WBC methylation has been found associated with an elevated risk of HGSOC and TNBC, under Norwegian law, this means that WBC BRCA1 methylation status may be considered predictive testing. Thus, our Regional Ethics Committee approved this part of the study provided no identification key or link to clinical information was stored. Thus, all molecular data from newborns in the present study were handled anonymously after analysis. Raw molecular data are available from the authors upon reasonable individual request, but any link to parameters in the MoBa databank is not possible.

Back to top
PreviousNext
Posted May 16, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
Oleksii Nikolaienko, Hans P. Eikesdal, Bjørnar Gilje, Steinar Lundgren, Egil S. Blix, Helge Espelid, Jürgen Geisler, Stephanie Geisler, Emiel A.M. Janssen, Synnøve Yndestad, Laura Minsaas, Beryl Leirvaag, Reidun Lillestøl, Stian Knappskog, Per E. Lønning
medRxiv 2023.05.14.23289949; doi: https://doi.org/10.1101/2023.05.14.23289949
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
Oleksii Nikolaienko, Hans P. Eikesdal, Bjørnar Gilje, Steinar Lundgren, Egil S. Blix, Helge Espelid, Jürgen Geisler, Stephanie Geisler, Emiel A.M. Janssen, Synnøve Yndestad, Laura Minsaas, Beryl Leirvaag, Reidun Lillestøl, Stian Knappskog, Per E. Lønning
medRxiv 2023.05.14.23289949; doi: https://doi.org/10.1101/2023.05.14.23289949

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)